EP3299027A1 — Use of complement pathway inhibitors to treat ocular diseases
Assigned to Genentech Inc · Expires 2018-03-28 · 8y expired
What this patent protects
The invention provides a complement inhibitor, in particular an antibody or an antigen-binding fragment thereof, as well as a pharmaceutical composition comprising same, for use in a method for treatment of an ocular disease associated with complement activation in a subject.
USPTO Abstract
The invention provides a complement inhibitor, in particular an antibody or an antigen-binding fragment thereof, as well as a pharmaceutical composition comprising same, for use in a method for treatment of an ocular disease associated with complement activation in a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.